Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer’s Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial
Authors
John A. Hey (ORCID: https://orcid.org/0000-0002-5104-6231)
Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer’s Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial
John A. Hey, Emer MacSweeney, Adem Albayrak, Anton P. Porsteinsson et al.
Citations
5 citations
Journal
Drugs
Topics
Neurological Disease Mechanisms and Treatments
Field-Weighted Citation Impact (FWCI)
4.21
article
Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer’s Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial
John A. Hey, Emer MacSweeney, Adem Albayrak, Anton P. Porsteinsson, Susan Flint, Yongxin Yu, Merçé Boada, Jean F. Schaefer, David Watson, Martin Tolar, Marwan Sabbagh, Rosalind McLaine, Sharon Cohen, J. Patrick Kesslak, Aidan Power, Sam Dickson, P. Murali Doraiswamy, Earvin Liang, Susan Abushakra, Luke Tolar
article en
5 citations
Abstract
No abstract available for this paper.
Publication Tag
DrugsVol. 85(11)
Institutions
Barrow Neurological Institute (US), Duke University (US), Universitat Internacional de Catalunya (ES), Alzheimer’s Disease Neuroimaging Initiative (US), TetraLogic Pharmaceuticals (United States) (US), Framingham State University (US), University of Rochester (US)
Funders
Göteborgs Universitet, National Institute on Aging